Detalles de la búsqueda
1.
Hereditary cancer risk assessment and genetic testing in the community urology practice setting.
Prostate
; 82(7): 850-857, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35239202
2.
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Ann Surg Oncol
; 27(3): 765-771, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31907749
3.
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.
Rheumatology (Oxford)
; 58(5): 874-883, 2019 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30590790
4.
An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.
Cancer
; 123(4): 617-628, 2017 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27768230
5.
Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.
J Cutan Pathol
; 42(4): 244-52, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25727210
6.
External validation of a multi-biomarker-based score for predicting risk of cardiovascular disease in patients with rheumatoid arthritis.
PLoS One
; 19(5): e0296459, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38709770
7.
Multi-year clinical outcomes of cancers diagnosed following detection by a blood-based multi-cancer early detection (MCED) test.
Cancer Prev Res (Phila)
; 2024 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38819783
8.
Outcomes following a false positive multi-cancer early detection (MCED) test: Results from DETECT-A, the first large, prospective, interventional MCED study.
Cancer Prev Res (Phila)
; 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38705577
9.
Outcomes Following a False-Positive Multi-Cancer Early Detection Test: Results from DETECT-A, the First Large, Prospective, Interventional MCED Study.
Cancer Prev Res (Phila)
; : OF1-OF5, 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38853442
10.
BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Gynecol Oncol
; 125(3): 677-82, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22406760
11.
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
Lancet Oncol
; 12(3): 245-55, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21310658
12.
Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.
Cancer Rep (Hoboken)
; 5(8): e1535, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34423592
13.
Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer.
Biomark Med
; 16(6): 449-459, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35321552
14.
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.
Int J Radiat Oncol Biol Phys
; 113(1): 66-76, 2022 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34610388
15.
Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment.
Clin Rheumatol
; 40(6): 2419-2426, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33237483
16.
Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Urol Oncol
; 39(6): 366.e19-366.e28, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33257218
17.
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy.
Clin Genitourin Cancer
; 19(4): 296-304.e3, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33608228
18.
Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies.
Arthritis Res Ther
; 23(1): 1, 2021 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33397438
19.
Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients.
Arthritis Res Ther
; 22(1): 282, 2020 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33276814
20.
Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores.
Clin Rheumatol
; 38(2): 437-445, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30159791